India, April 23 -- Addex Therapeutics Ltd. (ADXN), a clinical-stage biopharmaceutical company, announced on Wednesday that the Phase 1 trial for NTX-253 in treating schizophrenia, developed by spun-out company Neurosterix, is on track to conclude by the second quarter of 2026.
NTX-253 is an investigational, potent, selective, orally-available positive allosteric modulator (PAM) of the muscarinic M4 receptor. By modulating dopamine signaling, the drug can reduce psychotic symptoms while avoiding the movement disorders associated with other dopamine antagonists.
The Phase 1 trial consists of two parts, namely a single ascending dose (SAD) part and multiple ascending dose (MAD) part.
The Part 1 SAD study will dose healthy participants with ...